InVision AG: Q1 results in line with expectations; Remains a BUY
Yesterday, InVision released Q1 22 figures, which were fully in line with expectations. The highlight was once again the most important KPI, injixo ARR, as the company was able to improve this figure by +35 % yoy.
The full update is avaible on:
What's it all about ?
Yesterday, InVision released Q1 2022 figures, which were fully in line with expectations. The highlight was once again the most important KPI, injixo ARR (annual recurring revenue), as the company was able to improve this figure by +35% yoy to EUR 7.3m. This KPI represents the growth of InVision’s core product, the workforce management software (WFM) injixo. Offered as a SaaS-solution, injixo is the main pillar of InVision’s growth strategy. By 2025, the company targets c. EUR 50m in sales and an EBIT margin of 25%. In addition, liquid funds have increased to almost EUR 8.3m, which guarantees a financing until the break-even is reached (expected in 2024E eAR). Based on confirming figures and the overall growth perspectives, we reiterate our DCF-based BUY-rating with an unchanged price target of EUR 36.50.
https://www.research-hub.de/disclaimer